Emerging HER2-Targeted TKIs in Lung Cancer: Navigating the New Frontier in Precision Oncology
June 23, 2025
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
View More
PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
View More
Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?
View More
Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
A Progress Report on Chronic GVHD. The Grades Are Not So Great
June 24th 2025There has been no or some progress in most areas since a National Institute of Health consensus development project in 2020, according to a group of experts. But exception is important: Prevention of moderate or severe chronic graft-vs.-host disease.
Research and Funding Essential to Improving Postpartum Hemorrhage Outcomes
Ways health systems can support care teams treating postpartum hemorrhage and the potential impacts of the Trump administration’s diversity, equity and inclusion (DEI) policies, according to Abigail Wooldridge, assistant professor of Industrial and Enterprise Systems Engineering at the University of Illinois.
Women Pay More and Get Less from Employer Health Plans
June 19th 2025In a report by JPMorgan Chase's Morgan Health, it was found that 37% of women with employer-sponsored insurance said meeting their deductibles is difficult, and 36% reported that their plans didn’t cover care they expected—or paid less than anticipated.
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Headspace Joins Direct-to-Consumer Therapy Space With AI Companion, Ebb
Headspace has debuted a virtual therapy service called Therapy by Headspace that blends licensed care with AI support and insurance access to improve affordability and reach, according to a news release.